Table 1 Clinical trials of DNMT inhibitor monotherapies for solid tumors

Azacitidine

Solid tumors(breast cancer, melanoma, colon cancer)

1.0–24.0 mg/kg/day and were given over a minimal period of 8 days

I

30

SD:11/22 PD:11/22

1972

Solid tumor (breast cancer and other carcinoma)

1.6 mg/kg/day on days 1–10 and followed by a maintenance regimen

II

148

–

1977

CC-486

Relapsed or refractory solid tumors

300 mg/day (oral) on days 1–14 and day 21

I

20

PR:3/8 SD:4/8

2018

Fazarabine

Refractory metastatic colon cancer

2 mg/m²/h, continuous infusion 72 h every 3–4 weeks

II

18

–

1993

Refractory solid tumors

30 mg/m², daily bolus 5 times

I

–

–

1993

Decitabine

Metastatic solid tumors

20–40 mg/m²/day continuous infusion on days 1–3 (28-day cycle)

I

19

PD:14/14

2003

Solid tumors (ovarian, renal, breast, colon)

2 mg/m²/day 7-day continuous infusion (28-day cycle)

I

10

SD:2/9 PD:7/9

2005